Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is well-positioned for success due to its strong financial position, clear regulatory pathway, and diverse multi-indication strategy for its potential first-in-class therapy, Haduvio. Positive clinical data and a scalable development approach have significantly de-risked the outlook for Haduvio and its potential commercial success, with a runway for funding trials extending into 2028. However, there are still potential risks to consider, such as competition from a similar therapy from GSK expected to readout in 3Q26, and the need for additional financing for the large IPF cough Phase 3 study. Overall, as a financial analyst, there is a positive outlook for Trevi Therapeutics and the potential success of Haduvio in the treatment of chronic cough.

Bears say

Trevi Therapeutics is facing multiple risks, including clinical/regulatory risk, partnership and financial risk, commercial risk, legal and intellectual property risk, and market share risk. The company's updated IPF cough program, plans to conduct two phase 3 trials, and upcoming investor day may provide more clarity on its clinical development plans for Haduvio, but its success is still subject to regulatory input and dependent on the outcome of GlaxoSmithKline's phase 3 trial of camlipixant. The potential for partnership with GSK and Haduvio being the first and only FDA-approved treatment for RCC could present a positive outlook, but the company remains vulnerable to regulatory and competitive risks.

TRVI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 11 analysts, TRVI has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.